Accelerated Development of Additive Pharmacotherapy Treatment for Methamphetamine Use Disorder

Inclusion Criteria

• Be 18 to 65 years of age;
• Be able to speak English sufficiently to understand the study procedures and provide written informed consent to participate in the study;
• Demonstrate understanding of study procedures by correctly answering all questions on the consent competency tool;
• Be interested in reducing or stopping methamphetamine use;
• Meet DSM-5 criteria for severe methamphetamine use disorder;
• Meet subjective and objective methamphetamine use criteria as defined by the protocol;
• Meet subjective and objective measures of being opioid-free prior to enrollment and medication induction per study medical clinician's determination (including passing a naloxone challenge);
• Agree to use study cellphone to record videos of take-home dosing for transfer to study team.
• If female of childbearing potential, agree to use acceptable birth control methods during participation in the study;

Exclusion Criteria

• Have known allergy or sensitivity to study medications;
• Have a medical history or condition that would make study participation difficult or unsafe;
• Have an acute psychiatric disorder or condition that would make study participation difficult or unsafe;
• Liver function test results greater than 5 times the upper limit of normal or other exclusionary clinical lab test values;
• Recent or ongoing treatment with medications that, in the judgment of the study medical clinician, could interact adversely with study drugs or interfere with study participation;
• Have a current pattern of alcohol, benzodiazepine, or other sedative-hypnotic use, as determined by the study medical clinician, which would preclude safe participation;
• Pending action or situation that might prevent remaining in the area for the duration of the study or prevent participation in study activities
• Be currently pregnant or breastfeeding;